OBJECTIVE: Chromosome 22q11.2 deletion syndrome (22q11DS) confers 25% risk for psychosis and is an invaluable window for understanding the neurobiological substrate of psychosis risk. The Structured Interview for Prodromal Syndromes (SIPS) is well validated in nondeleted populations for detecting clinical risk but has only recently been applied to 22q11DS. We assessed the largest 22q11DS cohort to date and report on SIPS implementation and symptoms elicited. METHOD: The SIPS, including its 19 subscales, was administered to 157 individuals with 22q11DS aged 8 to 25 years. Youth and caregiver interviews were conducted and rated separately, then compared for agreement. Implementation of the SIPS in 22q11DS was challenging because of the prevalence of developmental delay and comorbid conditions. However, by explaining questions and eliciting examples, we were able to help youths and caregivers understand and respond appropriately. Consensus ratings were formulated and analyzed with itemwise and factor analysis. RESULTS: Subthreshold symptoms were common, with 85% of individuals endorsing 1 or more. The most commonly rated items were ideational richness (47%) and trouble with focus and attention (44%). Factor analysis revealed a 3-factor solution with positive, negative, and disorganized components. Youth-caregiver comparisons suggested that youths report greater symptoms of perceptual abnormalities, suspiciousness, trouble with emotional expression, and bizarre thinking. Caregivers reported more impaired tolerance to normal stress, poor hygiene, and inattention. CONCLUSION: The SIPS was adapted for 22q11DS through comprehensive and semi-structured administration methods, yielding a high prevalence of subthreshold psychotic symptoms. The significance and predictive validity of these symptoms require future longitudinal analysis.
OBJECTIVE: Chromosome 22q11.2 deletion syndrome (22q11DS) confers 25% risk for psychosis and is an invaluable window for understanding the neurobiological substrate of psychosis risk. The Structured Interview for Prodromal Syndromes (SIPS) is well validated in nondeleted populations for detecting clinical risk but has only recently been applied to 22q11DS. We assessed the largest 22q11DS cohort to date and report on SIPS implementation and symptoms elicited. METHOD: The SIPS, including its 19 subscales, was administered to 157 individuals with 22q11DS aged 8 to 25 years. Youth and caregiver interviews were conducted and rated separately, then compared for agreement. Implementation of the SIPS in 22q11DS was challenging because of the prevalence of developmental delay and comorbid conditions. However, by explaining questions and eliciting examples, we were able to help youths and caregivers understand and respond appropriately. Consensus ratings were formulated and analyzed with itemwise and factor analysis. RESULTS: Subthreshold symptoms were common, with 85% of individuals endorsing 1 or more. The most commonly rated items were ideational richness (47%) and trouble with focus and attention (44%). Factor analysis revealed a 3-factor solution with positive, negative, and disorganized components. Youth-caregiver comparisons suggested that youths report greater symptoms of perceptual abnormalities, suspiciousness, trouble with emotional expression, and bizarre thinking. Caregivers reported more impaired tolerance to normal stress, poor hygiene, and inattention. CONCLUSION: The SIPS was adapted for 22q11DS through comprehensive and semi-structured administration methods, yielding a high prevalence of subthreshold psychotic symptoms. The significance and predictive validity of these symptoms require future longitudinal analysis.
Authors: Larry J Seidman; Anthony J Giuliano; Eric C Meyer; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Bruce K Christensen; Keith Hawkins; Robert Heaton; Richard S E Keefe; Robert Heinssen; Barbara A Cornblatt Journal: Arch Gen Psychiatry Date: 2010-06
Authors: Maude Schneider; Martial Van der Linden; Bronwyn Glaser; Eleonora Rizzi; Sophie P Dahoun; Christine Hinard; Lucia Bartoloni; Stylianos E Antonarakis; Martin Debbané; Stephan Eliez Journal: Psychiatry Res Date: 2012-02-27 Impact factor: 3.222
Authors: Anne S Bassett; Donna M McDonald-McGinn; Koen Devriendt; Maria Cristina Digilio; Paula Goldenberg; Alex Habel; Bruno Marino; Solveig Oskarsdottir; Nicole Philip; Kathleen Sullivan; Ann Swillen; Jacob Vorstman Journal: J Pediatr Date: 2011-05-12 Impact factor: 4.406
Authors: A Comparelli; V Savoja; G D Kotzalidis; S W Woods; S Mosticoni; F Vassallo; F Soscia; R Piccione; G Palma; D Pucci; P Girardi; L Conti; R Tatarelli Journal: Epidemiol Psychiatr Sci Date: 2011-03 Impact factor: 6.892
Authors: Paula C Goldenberg; Monica E Calkins; Jan Richard; Donna McDonald-McGinn; Elaine Zackai; Nandita Mitra; Beverly Emanuel; Marcella Devoto; Karin Borgmann-Winter; Christian Kohler; Catherine G Conroy; Ruben C Gur; Raquel E Gur Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2011-12-13 Impact factor: 3.568
Authors: Kevin M Antshel; Robert Shprintzen; Wanda Fremont; Anne Marie Higgins; Stephen V Faraone; Wendy R Kates Journal: J Am Acad Child Adolesc Psychiatry Date: 2010-04 Impact factor: 8.829
Authors: Scott W Woods; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Robert Heinssen; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan Journal: Schizophr Bull Date: 2009-04-21 Impact factor: 9.306
Authors: Carina Heller; Saskia Steinmann; James J Levitt; Nikos Makris; Kevin M Antshel; Wanda Fremont; Ioana L Coman; Stefan R Schweinberger; Thomas Weiß; Sylvain Bouix; Marek R Kubicki; Wendy R Kates; Zora Kikinis Journal: Schizophr Res Date: 2020-10-23 Impact factor: 4.939
Authors: Cynthia B Solot; Tyler M Moore; Terrence Blaine Crowley; Marsha Gerdes; Edward Moss; Daniel E McGinn; Beverly S Emanuel; Elaine H Zackai; Sean Gallagher; Monica E Calkins; Kosha Ruparel; Ruben C Gur; Donna M McDonald-McGinn; Raquel E Gur Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2020-07-27 Impact factor: 3.568
Authors: Ehud Mekori-Domachevsky; Yael Guri; James Yi; Omri Weisman; Monica E Calkins; Sunny X Tang; Raz Gross; Donna M McDonald-McGinn; Beverly S Emanuel; Elaine H Zackai; Gil Zalsman; Abraham Weizman; Ruben C Gur; Raquel E Gur; Doron Gothelf Journal: Schizophr Res Date: 2016-12-29 Impact factor: 4.939
Authors: Charles Schleifer; Amy Lin; Leila Kushan; Jie Lisa Ji; Genevieve Yang; Carrie E Bearden; Alan Anticevic Journal: J Neurosci Date: 2018-11-26 Impact factor: 6.167
Authors: Sunny X Tang; Tyler M Moore; Monica E Calkins; James J Yi; Adam Savitt; Christian G Kohler; Margaret C Souders; Elaine H Zackai; Donna M McDonald-McGinn; Beverly S Emanuel; Ruben C Gur; Raquel E Gur Journal: Biol Psychiatry Date: 2016-09-08 Impact factor: 13.382
Authors: James J Yi; Ronnie Weinberger; Tyler M Moore; Monica E Calkins; Yael Guri; Donna M McDonald-McGinn; Elaine H Zackai; Beverly S Emanuel; Raquel E Gur; Doron Gothelf; Ruben C Gur Journal: Brain Cogn Date: 2016-05-17 Impact factor: 2.310